News & Publications

Press Releases

A New Approach to Treating Brain Cancer: HDT Bio Launches Canadian Clinical Program at McGill University

Jul 14, 2026

HDT Bio and UTMB Receive MCDC Innovation Prototype Award for Advancing CCHF Vaccine from Lab to Phase 1 Clinical Trial

May 21, 2026

SEATTLE, May 21, 2026 /PRNewswire/ -- HDT Bio, a clinical-stage biotechnology company based in Seattle, Washington, today announced that it received the Medical CBRN Defense Consortium (MCDC) Innovation Prototype Award. The award recognizes HDT Bio's MCDC project...

FDA Greenlights HDT Bio’s First-in-Class HDT-321 for the Prevention of Deadly Tick-Borne Disease

Sep 22, 2025

SEATTLE, Sept. 19, 2025 /PRNewswire/ -- HDT Bio Corporation, a U.S.-based clinical-stage biotechnology company advancing immune-enhancing solutions for global health, biodefense, and oncology, today announced that the U.S. Food and Drug Administration (FDA) has...

MalarVx licenses HDT Bio’s repRNA/LION™ Technology for Novel Malaria Vaccine

Jan 24, 2025

HDT Bio's LION™ platform to support malaria vaccine development by MalarVx SEATTLE, Jan. 15, 2025 /PRNewswire/ -- MalarVx, Inc., a clinical-stage vaccine company, is proud to announce a license to HDT Bio's proprietary self-amplifying replicon RNA (repRNA) and lipid...

HDT Bio to Help Spearhead RNA Vaccine Development in National Pandemic Preparedness Initiative

Sep 17, 2024

HDT bio's Rapid-Response Roadmap for RNA vaccines (R4) project granted a five-year subaward for $2M per year SEATTLE, Sept. 17, 2024 /PRNewswire/ -- HDT Bio Corp., a clinical-stage biopharmaceutical company specializing in advanced RNA vaccine technologies, is proud...